Prostate Cancer

According to the American Cancer Society, about 1 in 7 men in the U.S. will be diagnosed with prostate cancer in his lifetime.

The disease often occurs in older men, with the average age at diagnosis being 66 years old. 

GoPath has developed several molecular tests to diagnose prostate cancer and to predict prognosis. Our tests yield results that help your doctor create a treatment plan that is tailor-made to best treat your particular type of prostate cancer. 

These tests include:

          •     GoProDxTM - Indicates prognosis for prostate cancer via PTEN/ERG 
          •     PCA3 - Used to determine whether or not you should have a prostate biopsy
          •     PTEN FISH - Test that uses FISH technology to examine the PTEN biomarker
          •     ERG IHC - Test that uses IHC technology to examine the ERG biomarker
          •     OncoTargetTM - Detects genetic mutations in a tumor that may lead to treatment resistance
          •     Prostate Biopsy